Japan Pharmaceuticals and Healthcare Report Q1 2015
Includes 3 FREE quarterly updates
LONDON, Nov. 20, 2014 /PRNewswire/ --
BMI View:
The Japanese pharmaceutical market continues to hold strong rewards for innovative pharmaceutical companies. This is driven by the country's rapidly ageing population, preference for branded medicines and strong public coverage of drug expenditure. However, the cost containment measures by the government including aggressively cutting medicine prices pose a downward risk to the market's long term growth.
Risk/Reward Index
Japan's Pharmaceutical Risk/Reward Index (RRI) score for Q115 increased to 78.1 out of the maximum 100 in our newly improved RRR system. This high score makes Japan the most attractive country in comparison with the other 18 key Asia Pacific markets, followed by South Korea (68.6) and Australia (67.0). Japan's score is boosted by the large multi-billion dollar drug market (market expenditure score of 18.0 out of 20) and large pensionable population (pensionable population score of 8.0 out of 8), but dragged down by a declining pharmaceutical market (sector value growth score of 3.6 out of 12) and a declining population (population growth score of 1.0 out of 5). Thus, Japan's ageing population will translate into increased pharmaceutical sales although with relatively low growth prospects over the long term.
Download the full report: https://www.reportbuyer.com/product/169817/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article